| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Carcinoma, Renal Cell | 406 | 2024 | 3142 | 49.010 |
Why?
|
| Kidney Neoplasms | 396 | 2024 | 4260 | 41.580 |
Why?
|
| Anilides | 30 | 2022 | 409 | 7.440 |
Why?
|
| Antineoplastic Agents | 136 | 2023 | 13691 | 6.620 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 111 | 2024 | 11524 | 6.620 |
Why?
|
| Pyrroles | 52 | 2018 | 1147 | 6.500 |
Why?
|
| Vascular Endothelial Growth Factor A | 63 | 2023 | 3510 | 5.790 |
Why?
|
| Indoles | 52 | 2018 | 1841 | 5.710 |
Why?
|
| Angiogenesis Inhibitors | 45 | 2022 | 2037 | 5.040 |
Why?
|
| Nephrectomy | 43 | 2023 | 1048 | 4.890 |
Why?
|
| Pyridines | 45 | 2022 | 2827 | 4.590 |
Why?
|
| Molecular Targeted Therapy | 57 | 2021 | 2727 | 4.580 |
Why?
|
| Urologic Neoplasms | 27 | 2020 | 318 | 3.990 |
Why?
|
| Carcinoma, Transitional Cell | 33 | 2023 | 808 | 3.970 |
Why?
|
| Protein Kinase Inhibitors | 62 | 2023 | 5532 | 3.610 |
Why?
|
| Urinary Bladder Neoplasms | 43 | 2023 | 2248 | 3.460 |
Why?
|
| Prostatic Neoplasms | 109 | 2023 | 11059 | 3.320 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 17 | 2018 | 664 | 3.110 |
Why?
|
| Phenylurea Compounds | 33 | 2024 | 528 | 3.110 |
Why?
|
| Neoplasm Metastasis | 81 | 2023 | 4848 | 3.090 |
Why?
|
| Disease-Free Survival | 78 | 2021 | 6895 | 2.690 |
Why?
|
| Niacinamide | 27 | 2017 | 416 | 2.650 |
Why?
|
| Antibodies, Monoclonal | 38 | 2023 | 9272 | 2.610 |
Why?
|
| TOR Serine-Threonine Kinases | 32 | 2022 | 2110 | 2.540 |
Why?
|
| Proto-Oncogene Proteins c-met | 11 | 2020 | 579 | 2.360 |
Why?
|
| Androgen Antagonists | 33 | 2023 | 1376 | 2.350 |
Why?
|
| Humans | 724 | 2024 | 743811 | 2.340 |
Why?
|
| Neoplasms | 76 | 2023 | 21675 | 2.320 |
Why?
|
| Aged | 325 | 2024 | 163178 | 2.150 |
Why?
|
| Middle Aged | 333 | 2024 | 213241 | 2.150 |
Why?
|
| Indazoles | 30 | 2021 | 290 | 2.140 |
Why?
|
| Cystectomy | 14 | 2018 | 686 | 2.110 |
Why?
|
| Survival Analysis | 69 | 2024 | 10251 | 2.070 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 7 | 2023 | 1114 | 2.060 |
Why?
|
| Male | 427 | 2024 | 349776 | 2.050 |
Why?
|
| Sirolimus | 17 | 2023 | 1565 | 1.960 |
Why?
|
| Urothelium | 13 | 2017 | 277 | 1.890 |
Why?
|
| Sulfonamides | 24 | 2021 | 1938 | 1.820 |
Why?
|
| Immunotherapy | 36 | 2023 | 4437 | 1.810 |
Why?
|
| Prognosis | 106 | 2023 | 29052 | 1.790 |
Why?
|
| Clinical Trials, Phase II as Topic | 27 | 2024 | 629 | 1.750 |
Why?
|
| Benzenesulfonates | 16 | 2012 | 169 | 1.670 |
Why?
|
| Treatment Outcome | 149 | 2023 | 63042 | 1.670 |
Why?
|
| Pyrimidines | 27 | 2022 | 2945 | 1.640 |
Why?
|
| Kaplan-Meier Estimate | 46 | 2021 | 6539 | 1.640 |
Why?
|
| Female | 319 | 2024 | 380020 | 1.640 |
Why?
|
| Aged, 80 and over | 139 | 2023 | 57744 | 1.630 |
Why?
|
| Bone Neoplasms | 10 | 2019 | 2529 | 1.610 |
Why?
|
| Prostate-Specific Antigen | 29 | 2023 | 2471 | 1.490 |
Why?
|
| Prostatectomy | 29 | 2019 | 1879 | 1.450 |
Why?
|
| Vinblastine | 8 | 2019 | 501 | 1.420 |
Why?
|
| Survival Rate | 58 | 2021 | 12786 | 1.400 |
Why?
|
| Antineoplastic Agents, Hormonal | 17 | 2023 | 1523 | 1.380 |
Why?
|
| Clinical Trials, Phase III as Topic | 24 | 2022 | 841 | 1.360 |
Why?
|
| SEER Program | 40 | 2023 | 1507 | 1.280 |
Why?
|
| Retrospective Studies | 137 | 2024 | 77410 | 1.250 |
Why?
|
| Quinolines | 6 | 2024 | 732 | 1.220 |
Why?
|
| Neoplasm Staging | 60 | 2021 | 11036 | 1.190 |
Why?
|
| Triazines | 2 | 2020 | 315 | 1.150 |
Why?
|
| Cisplatin | 14 | 2020 | 1662 | 1.140 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 6 | 2021 | 290 | 1.120 |
Why?
|
| Carcinoma, Papillary | 6 | 2015 | 783 | 1.110 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 4 | 2020 | 547 | 1.090 |
Why?
|
| Mutation | 44 | 2024 | 29777 | 1.080 |
Why?
|
| Adult | 157 | 2023 | 213889 | 1.060 |
Why?
|
| Gene Expression Regulation, Neoplastic | 30 | 2022 | 8430 | 1.060 |
Why?
|
| Healthcare Disparities | 18 | 2023 | 3155 | 1.050 |
Why?
|
| Drug Resistance, Neoplasm | 15 | 2021 | 5170 | 1.020 |
Why?
|
| Chemotherapy, Adjuvant | 24 | 2021 | 3480 | 1.010 |
Why?
|
| Neoadjuvant Therapy | 19 | 2019 | 2727 | 1.010 |
Why?
|
| Carbonic Anhydrases | 3 | 2024 | 115 | 0.990 |
Why?
|
| Neoplasm Recurrence, Local | 25 | 2023 | 9239 | 0.990 |
Why?
|
| Germ-Line Mutation | 7 | 2022 | 1787 | 0.980 |
Why?
|
| Medical Oncology | 14 | 2023 | 2267 | 0.960 |
Why?
|
| Pyrazines | 3 | 2020 | 1230 | 0.960 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 6 | 2021 | 1660 | 0.950 |
Why?
|
| Follow-Up Studies | 61 | 2023 | 39001 | 0.940 |
Why?
|
| Endogenous Retroviruses | 2 | 2022 | 112 | 0.940 |
Why?
|
| Randomized Controlled Trials as Topic | 39 | 2022 | 9944 | 0.940 |
Why?
|
| Protective Agents | 2 | 2014 | 156 | 0.900 |
Why?
|
| Clinical Trials as Topic | 38 | 2021 | 7908 | 0.890 |
Why?
|
| Imidazoles | 8 | 2017 | 1206 | 0.890 |
Why?
|
| Databases, Factual | 39 | 2021 | 7729 | 0.880 |
Why?
|
| Salvage Therapy | 13 | 2019 | 1275 | 0.860 |
Why?
|
| Urogenital Neoplasms | 2 | 2020 | 137 | 0.830 |
Why?
|
| Proportional Hazards Models | 41 | 2023 | 12354 | 0.830 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 2 | 2014 | 648 | 0.790 |
Why?
|
| Taxoids | 7 | 2017 | 666 | 0.750 |
Why?
|
| Ubiquitin Thiolesterase | 6 | 2021 | 449 | 0.750 |
Why?
|
| Genomics | 19 | 2023 | 5714 | 0.730 |
Why?
|
| Combined Modality Therapy | 24 | 2023 | 8637 | 0.720 |
Why?
|
| Therapies, Investigational | 1 | 2021 | 112 | 0.710 |
Why?
|
| Adrenocortical Carcinoma | 3 | 2016 | 88 | 0.700 |
Why?
|
| Neoplasms, Second Primary | 7 | 2018 | 1063 | 0.690 |
Why?
|
| Interleukin-8 | 2 | 2020 | 690 | 0.690 |
Why?
|
| Testicular Neoplasms | 7 | 2018 | 803 | 0.680 |
Why?
|
| Chromosomes, Human, X | 3 | 2015 | 296 | 0.670 |
Why?
|
| Pandemics | 15 | 2023 | 8385 | 0.670 |
Why?
|
| Immunoconjugates | 3 | 2023 | 901 | 0.670 |
Why?
|
| Carcinoma | 9 | 2023 | 2375 | 0.660 |
Why?
|
| Rhabdoid Tumor | 1 | 2021 | 212 | 0.660 |
Why?
|
| Lymphocytes | 5 | 2023 | 2615 | 0.660 |
Why?
|
| Immunologic Factors | 6 | 2021 | 1580 | 0.640 |
Why?
|
| HSP27 Heat-Shock Proteins | 1 | 2018 | 69 | 0.630 |
Why?
|
| Brain Neoplasms | 11 | 2023 | 8856 | 0.630 |
Why?
|
| Coronavirus Infections | 6 | 2020 | 3134 | 0.620 |
Why?
|
| Radiosurgery | 3 | 2023 | 1331 | 0.620 |
Why?
|
| Pneumonia, Viral | 6 | 2020 | 3241 | 0.620 |
Why?
|
| Radium | 1 | 2018 | 65 | 0.620 |
Why?
|
| Translocation, Genetic | 4 | 2018 | 1420 | 0.620 |
Why?
|
| Risk Factors | 73 | 2023 | 72252 | 0.610 |
Why?
|
| Indans | 1 | 2017 | 96 | 0.600 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 10 | 2021 | 1038 | 0.590 |
Why?
|
| Time Factors | 44 | 2021 | 40038 | 0.580 |
Why?
|
| Early Detection of Cancer | 12 | 2023 | 3089 | 0.570 |
Why?
|
| Thromboembolism | 3 | 2012 | 987 | 0.570 |
Why?
|
| Drug Administration Schedule | 13 | 2019 | 4931 | 0.560 |
Why?
|
| Deoxycytidine | 3 | 2017 | 826 | 0.560 |
Why?
|
| Adrenal Cortex Neoplasms | 2 | 2016 | 162 | 0.550 |
Why?
|
| Neoplasm Proteins | 9 | 2019 | 3706 | 0.540 |
Why?
|
| Melanoma | 9 | 2024 | 5508 | 0.540 |
Why?
|
| Disease Progression | 26 | 2023 | 13273 | 0.540 |
Why?
|
| Tumor Burden | 6 | 2022 | 1917 | 0.530 |
Why?
|
| Antigens, Neoplasm | 5 | 2024 | 1988 | 0.530 |
Why?
|
| Quality of Life | 18 | 2024 | 12788 | 0.530 |
Why?
|
| Hand Joints | 1 | 2016 | 53 | 0.530 |
Why?
|
| Gene Expression Profiling | 19 | 2021 | 9440 | 0.530 |
Why?
|
| Isoflavones | 2 | 2006 | 139 | 0.510 |
Why?
|
| Orchiectomy | 6 | 2016 | 468 | 0.510 |
Why?
|
| Sulfones | 1 | 2017 | 434 | 0.510 |
Why?
|
| Registries | 10 | 2023 | 8090 | 0.510 |
Why?
|
| Tumor Suppressor Proteins | 7 | 2021 | 2850 | 0.510 |
Why?
|
| Oligonucleotides | 1 | 2018 | 572 | 0.510 |
Why?
|
| Standard of Care | 2 | 2018 | 564 | 0.490 |
Why?
|
| Neutrophils | 5 | 2022 | 3718 | 0.490 |
Why?
|
| Patient Selection | 10 | 2021 | 4210 | 0.490 |
Why?
|
| United States | 70 | 2023 | 69859 | 0.490 |
Why?
|
| Young Adult | 35 | 2021 | 56392 | 0.490 |
Why?
|
| Dose-Response Relationship, Drug | 13 | 2021 | 10940 | 0.490 |
Why?
|
| Angiotensins | 1 | 2015 | 151 | 0.490 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2021 | 152 | 0.480 |
Why?
|
| ABO Blood-Group System | 2 | 2015 | 367 | 0.470 |
Why?
|
| Cohort Studies | 39 | 2023 | 40545 | 0.450 |
Why?
|
| Lung Neoplasms | 13 | 2024 | 13112 | 0.450 |
Why?
|
| Risk Assessment | 42 | 2021 | 23327 | 0.450 |
Why?
|
| Risk | 14 | 2018 | 9677 | 0.440 |
Why?
|
| High-Throughput Nucleotide Sequencing | 13 | 2021 | 3591 | 0.440 |
Why?
|
| Infection Control | 1 | 2020 | 964 | 0.440 |
Why?
|
| Neoplasms, Multiple Primary | 2 | 2014 | 604 | 0.430 |
Why?
|
| Logistic Models | 23 | 2019 | 13404 | 0.430 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p16 | 4 | 2021 | 705 | 0.420 |
Why?
|
| Vascular Endothelial Growth Factors | 3 | 2011 | 771 | 0.420 |
Why?
|
| Uveitis | 1 | 2016 | 374 | 0.420 |
Why?
|
| Proton Pump Inhibitors | 1 | 2017 | 526 | 0.420 |
Why?
|
| Prospective Studies | 36 | 2023 | 53250 | 0.410 |
Why?
|
| Hepatocyte Growth Factor | 1 | 2013 | 270 | 0.410 |
Why?
|
| Tumor Microenvironment | 10 | 2023 | 3583 | 0.410 |
Why?
|
| Nomograms | 3 | 2020 | 228 | 0.400 |
Why?
|
| Renin-Angiotensin System | 2 | 2022 | 758 | 0.400 |
Why?
|
| Intention to Treat Analysis | 3 | 2021 | 426 | 0.400 |
Why?
|
| Vinca Alkaloids | 1 | 2011 | 35 | 0.390 |
Why?
|
| Neoplasms, Hormone-Dependent | 3 | 2014 | 413 | 0.390 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2020 | 627 | 0.380 |
Why?
|
| Signal Transduction | 27 | 2022 | 23398 | 0.380 |
Why?
|
| Double-Blind Method | 9 | 2023 | 12020 | 0.380 |
Why?
|
| Immunohistochemistry | 16 | 2019 | 11360 | 0.370 |
Why?
|
| Nuclear Proteins | 6 | 2022 | 5854 | 0.370 |
Why?
|
| Hyponatremia | 1 | 2013 | 297 | 0.370 |
Why?
|
| Adenocarcinoma | 8 | 2022 | 6363 | 0.370 |
Why?
|
| DNA-Binding Proteins | 11 | 2022 | 9648 | 0.370 |
Why?
|
| Arthritis | 1 | 2016 | 661 | 0.370 |
Why?
|
| Neoplasms, Germ Cell and Embryonal | 3 | 2017 | 501 | 0.360 |
Why?
|
| Treatment Failure | 9 | 2013 | 2617 | 0.360 |
Why?
|
| Organoplatinum Compounds | 4 | 2017 | 408 | 0.360 |
Why?
|
| Incidence | 26 | 2023 | 20948 | 0.360 |
Why?
|
| Hemorrhage | 3 | 2022 | 3458 | 0.360 |
Why?
|
| Phosphatidylinositol 3-Kinases | 7 | 2022 | 2938 | 0.350 |
Why?
|
| Bone Density Conservation Agents | 2 | 2014 | 768 | 0.350 |
Why?
|
| Transcription Factors | 10 | 2023 | 12209 | 0.350 |
Why?
|
| Polyethylene Glycols | 5 | 2022 | 1181 | 0.350 |
Why?
|
| Odds Ratio | 18 | 2022 | 9848 | 0.340 |
Why?
|
| Metformin | 1 | 2016 | 837 | 0.340 |
Why?
|
| Venous Thromboembolism | 4 | 2022 | 1670 | 0.340 |
Why?
|
| Diphosphonates | 1 | 2014 | 622 | 0.340 |
Why?
|
| Genetic Association Studies | 3 | 2021 | 2703 | 0.340 |
Why?
|
| Topoisomerase II Inhibitors | 2 | 2006 | 87 | 0.340 |
Why?
|
| Chromosomes, Human, Pair 11 | 2 | 2009 | 417 | 0.330 |
Why?
|
| Endonucleases | 3 | 2017 | 380 | 0.330 |
Why?
|
| Brachytherapy | 10 | 2018 | 1247 | 0.330 |
Why?
|
| Biomedical Research | 2 | 2022 | 3308 | 0.320 |
Why?
|
| Microphthalmia-Associated Transcription Factor | 2 | 2022 | 252 | 0.320 |
Why?
|
| Liver Neoplasms | 6 | 2023 | 4251 | 0.320 |
Why?
|
| Carcinoma, Non-Small-Cell Lung | 6 | 2024 | 5230 | 0.310 |
Why?
|
| Sodium | 1 | 2013 | 1622 | 0.310 |
Why?
|
| Sarcoma | 1 | 2019 | 1898 | 0.310 |
Why?
|
| Predictive Value of Tests | 18 | 2021 | 15067 | 0.310 |
Why?
|
| Weight Loss | 1 | 2019 | 2625 | 0.310 |
Why?
|
| Marital Status | 5 | 2016 | 437 | 0.300 |
Why?
|
| Genetic Predisposition to Disease | 17 | 2022 | 17439 | 0.300 |
Why?
|
| Autoimmune Diseases | 2 | 2018 | 2134 | 0.300 |
Why?
|
| Hospitals | 8 | 2023 | 3953 | 0.300 |
Why?
|
| Prostate | 7 | 2022 | 1763 | 0.290 |
Why?
|
| Hematologic Diseases | 1 | 2011 | 498 | 0.290 |
Why?
|
| Insurance, Health | 5 | 2019 | 2492 | 0.290 |
Why?
|
| Interferon-alpha | 3 | 2018 | 895 | 0.290 |
Why?
|
| Watchful Waiting | 4 | 2020 | 491 | 0.290 |
Why?
|
| Basic Helix-Loop-Helix Leucine Zipper Transcription Factors | 3 | 2022 | 315 | 0.280 |
Why?
|
| Drug Delivery Systems | 6 | 2011 | 2217 | 0.280 |
Why?
|
| Tomography, X-Ray Computed | 9 | 2022 | 20121 | 0.280 |
Why?
|
| Analgesics | 1 | 2013 | 1040 | 0.280 |
Why?
|
| Age Factors | 20 | 2020 | 18355 | 0.280 |
Why?
|
| Cryosurgery | 1 | 2011 | 453 | 0.280 |
Why?
|
| Forecasting | 5 | 2019 | 2950 | 0.280 |
Why?
|
| Administration, Oral | 8 | 2022 | 3912 | 0.270 |
Why?
|
| Single-Blind Method | 2 | 2020 | 1586 | 0.270 |
Why?
|
| Acute Kidney Injury | 4 | 2021 | 1968 | 0.270 |
Why?
|
| Histone-Lysine N-Methyltransferase | 4 | 2020 | 671 | 0.270 |
Why?
|
| Recurrence | 8 | 2021 | 8337 | 0.270 |
Why?
|
| Interleukin-2 | 4 | 2015 | 1904 | 0.270 |
Why?
|
| Protein-Tyrosine Kinases | 3 | 2011 | 2453 | 0.260 |
Why?
|
| CD8-Positive T-Lymphocytes | 7 | 2022 | 4477 | 0.260 |
Why?
|
| Gonadotropin-Releasing Hormone | 4 | 2018 | 1205 | 0.260 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2010 | 793 | 0.260 |
Why?
|
| Interleukin-7 | 2 | 2022 | 142 | 0.260 |
Why?
|
| DNA Copy Number Variations | 10 | 2023 | 1937 | 0.260 |
Why?
|
| Multivariate Analysis | 17 | 2018 | 12243 | 0.260 |
Why?
|
| RNA, Neoplasm | 4 | 2016 | 769 | 0.260 |
Why?
|
| Neovascularization, Pathologic | 4 | 2020 | 2638 | 0.250 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2022 | 933 | 0.250 |
Why?
|
| Thalidomide | 2 | 2006 | 890 | 0.250 |
Why?
|
| Arrhythmias, Cardiac | 1 | 2014 | 2267 | 0.250 |
Why?
|
| Ureteral Neoplasms | 2 | 2016 | 111 | 0.240 |
Why?
|
| Platinum Compounds | 3 | 2017 | 96 | 0.240 |
Why?
|
| Rare Diseases | 2 | 2020 | 552 | 0.240 |
Why?
|
| Paclitaxel | 6 | 2019 | 1705 | 0.240 |
Why?
|
| DNA Methylation | 8 | 2022 | 4286 | 0.230 |
Why?
|
| Cell Line, Tumor | 10 | 2023 | 16674 | 0.230 |
Why?
|
| Osteoporosis | 1 | 2013 | 1577 | 0.230 |
Why?
|
| Kallikreins | 4 | 2018 | 256 | 0.230 |
Why?
|
| Hemoglobins | 5 | 2017 | 1531 | 0.230 |
Why?
|
| Polymorphism, Single Nucleotide | 8 | 2019 | 15518 | 0.230 |
Why?
|
| Telemedicine | 4 | 2021 | 2874 | 0.230 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2017 | 2504 | 0.230 |
Why?
|
| Neoplasm Invasiveness | 9 | 2018 | 3617 | 0.230 |
Why?
|
| Gene Expression | 7 | 2022 | 7793 | 0.230 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2016 | 2039 | 0.230 |
Why?
|
| Tissue Extracts | 2 | 2017 | 135 | 0.230 |
Why?
|
| Kidney | 10 | 2023 | 7185 | 0.220 |
Why?
|
| Models, Biological | 5 | 2013 | 9582 | 0.220 |
Why?
|
| Genome, Human | 5 | 2018 | 4418 | 0.220 |
Why?
|
| Breast Neoplasms | 13 | 2021 | 20827 | 0.220 |
Why?
|
| PTEN Phosphohydrolase | 3 | 2020 | 1142 | 0.220 |
Why?
|
| Hypothyroidism | 2 | 2018 | 659 | 0.220 |
Why?
|
| Socioeconomic Factors | 11 | 2020 | 7784 | 0.220 |
Why?
|
| Health Services Accessibility | 5 | 2023 | 5136 | 0.220 |
Why?
|
| Postoperative Complications | 6 | 2017 | 15281 | 0.220 |
Why?
|
| Glomerular Filtration Rate | 4 | 2021 | 2167 | 0.210 |
Why?
|
| Anti-Bacterial Agents | 2 | 2019 | 7172 | 0.210 |
Why?
|
| Paraneoplastic Syndromes | 1 | 2024 | 151 | 0.210 |
Why?
|
| Quinazolines | 4 | 2014 | 1356 | 0.210 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 4 | 2023 | 3255 | 0.210 |
Why?
|
| Fatigue | 3 | 2019 | 1530 | 0.210 |
Why?
|
| International Cooperation | 5 | 2020 | 1419 | 0.210 |
Why?
|
| Penile Neoplasms | 1 | 2023 | 161 | 0.210 |
Why?
|
| HLA-A3 Antigen | 1 | 2021 | 34 | 0.210 |
Why?
|
| Boston | 3 | 2024 | 9310 | 0.210 |
Why?
|
| Ischemia | 1 | 2010 | 1907 | 0.200 |
Why?
|
| Clinical Trials, Phase I as Topic | 4 | 2020 | 323 | 0.200 |
Why?
|
| Insurance Coverage | 4 | 2019 | 1900 | 0.200 |
Why?
|
| Butylamines | 1 | 2021 | 8 | 0.200 |
Why?
|
| Amylases | 2 | 2019 | 173 | 0.200 |
Why?
|
| Genealogy and Heraldry | 1 | 2021 | 28 | 0.200 |
Why?
|
| Adenoma | 1 | 2012 | 2173 | 0.200 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 1 | 2011 | 2281 | 0.200 |
Why?
|
| Up-Regulation | 3 | 2022 | 4221 | 0.200 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2021 | 83 | 0.200 |
Why?
|
| Benzoxazoles | 1 | 2022 | 79 | 0.200 |
Why?
|
| Myocarditis | 2 | 2019 | 768 | 0.190 |
Why?
|
| Erythropoietin | 2 | 2021 | 726 | 0.190 |
Why?
|
| Medically Uninsured | 3 | 2016 | 853 | 0.190 |
Why?
|
| Lymph Node Excision | 4 | 2017 | 1262 | 0.190 |
Why?
|
| Radiotherapy, Adjuvant | 6 | 2017 | 1770 | 0.190 |
Why?
|
| Receptors, Androgen | 3 | 2022 | 1055 | 0.190 |
Why?
|
| Immune System Diseases | 1 | 2023 | 261 | 0.190 |
Why?
|
| Telangiectasia, Hereditary Hemorrhagic | 1 | 2002 | 139 | 0.190 |
Why?
|
| Aminoquinolines | 1 | 2021 | 109 | 0.190 |
Why?
|
| Diarrhea | 2 | 2019 | 1348 | 0.190 |
Why?
|
| Heart Failure | 4 | 2014 | 10896 | 0.190 |
Why?
|
| Lymphatic Metastasis | 7 | 2017 | 2924 | 0.190 |
Why?
|
| Models, Statistical | 1 | 2015 | 5100 | 0.190 |
Why?
|
| Infectious Disease Transmission, Professional-to-Patient | 1 | 2020 | 35 | 0.190 |
Why?
|
| Minority Health | 2 | 2019 | 87 | 0.190 |
Why?
|
| Cause of Death | 10 | 2022 | 3580 | 0.190 |
Why?
|
| Aromatase Inhibitors | 1 | 2004 | 487 | 0.190 |
Why?
|
| Health Expenditures | 3 | 2020 | 2348 | 0.190 |
Why?
|
| Telomerase | 2 | 2024 | 731 | 0.180 |
Why?
|
| Guidelines as Topic | 3 | 2015 | 1404 | 0.180 |
Why?
|
| ROC Curve | 3 | 2014 | 3527 | 0.180 |
Why?
|
| Camptothecin | 1 | 2023 | 576 | 0.180 |
Why?
|
| Georgia | 1 | 2020 | 187 | 0.180 |
Why?
|
| Hypertension | 6 | 2022 | 8480 | 0.180 |
Why?
|
| Pneumonia | 1 | 2012 | 2133 | 0.180 |
Why?
|
| Comparative Effectiveness Research | 3 | 2020 | 680 | 0.180 |
Why?
|
| Phenotype | 11 | 2023 | 16361 | 0.180 |
Why?
|
| Cell Respiration | 1 | 2020 | 199 | 0.180 |
Why?
|
| p300-CBP Transcription Factors | 1 | 2021 | 147 | 0.180 |
Why?
|
| DNA Mutational Analysis | 5 | 2018 | 4183 | 0.180 |
Why?
|
| Radiography | 3 | 2016 | 7010 | 0.180 |
Why?
|
| Thyroid Neoplasms | 2 | 2024 | 2282 | 0.180 |
Why?
|
| Cancer Care Facilities | 3 | 2017 | 402 | 0.170 |
Why?
|
| Maximum Tolerated Dose | 5 | 2021 | 892 | 0.170 |
Why?
|
| 5'-Nucleotidase | 1 | 2020 | 160 | 0.170 |
Why?
|
| Lipase | 2 | 2019 | 314 | 0.170 |
Why?
|
| Genome-Wide Association Study | 6 | 2022 | 12259 | 0.170 |
Why?
|
| Head and Neck Neoplasms | 2 | 2024 | 2736 | 0.170 |
Why?
|
| Penetrance | 1 | 2021 | 381 | 0.170 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2019 | 124 | 0.170 |
Why?
|
| Genes, Neoplasm | 1 | 2021 | 376 | 0.170 |
Why?
|
| Databases, Genetic | 3 | 2021 | 1782 | 0.170 |
Why?
|
| Chromosomes, Human, Pair 6 | 1 | 2020 | 380 | 0.170 |
Why?
|
| Skin Neoplasms | 2 | 2021 | 5691 | 0.170 |
Why?
|
| Therapeutics | 1 | 2019 | 116 | 0.170 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 2020 | 104 | 0.170 |
Why?
|
| Viruses | 1 | 2022 | 374 | 0.170 |
Why?
|
| Alanine Transaminase | 2 | 2019 | 593 | 0.170 |
Why?
|
| Spain | 1 | 2020 | 464 | 0.160 |
Why?
|
| Canada | 3 | 2020 | 2064 | 0.160 |
Why?
|
| Regression Analysis | 7 | 2017 | 6457 | 0.160 |
Why?
|
| Drugs, Investigational | 1 | 2021 | 214 | 0.160 |
Why?
|
| Biology | 1 | 2021 | 295 | 0.160 |
Why?
|
| Tyrosine | 1 | 2023 | 1462 | 0.160 |
Why?
|
| Purpura, Thrombocytopenic, Idiopathic | 1 | 2002 | 234 | 0.160 |
Why?
|
| Receptor, erbB-2 | 5 | 2016 | 2418 | 0.160 |
Why?
|
| Income | 4 | 2014 | 1913 | 0.160 |
Why?
|
| Class I Phosphatidylinositol 3-Kinases | 2 | 2020 | 890 | 0.160 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2020 | 535 | 0.160 |
Why?
|
| Cyclic AMP Response Element-Binding Protein | 1 | 2021 | 514 | 0.160 |
Why?
|
| Sequence Analysis, RNA | 4 | 2020 | 2009 | 0.160 |
Why?
|
| Observer Variation | 3 | 2015 | 2592 | 0.160 |
Why?
|
| Adolescent | 15 | 2021 | 85729 | 0.160 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 2 | 2018 | 105 | 0.160 |
Why?
|
| Divorce | 1 | 2018 | 79 | 0.160 |
Why?
|
| Drug Repositioning | 1 | 2020 | 230 | 0.160 |
Why?
|
| Glutathione Peroxidase | 1 | 2019 | 255 | 0.150 |
Why?
|
| Pyrophosphatases | 1 | 2018 | 137 | 0.150 |
Why?
|
| In Situ Hybridization, Fluorescence | 5 | 2023 | 2649 | 0.150 |
Why?
|
| Carcinoma, Neuroendocrine | 1 | 2022 | 332 | 0.150 |
Why?
|
| Medicare | 6 | 2019 | 6565 | 0.150 |
Why?
|
| Hospital Costs | 2 | 2016 | 985 | 0.150 |
Why?
|
| Chromosome Deletion | 2 | 2020 | 1396 | 0.150 |
Why?
|
| Catheter Ablation | 1 | 2011 | 2758 | 0.150 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2020 | 3020 | 0.150 |
Why?
|
| Polymyalgia Rheumatica | 1 | 2017 | 54 | 0.150 |
Why?
|
| Drug Dosage Calculations | 1 | 2018 | 114 | 0.150 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 253 | 0.150 |
Why?
|
| Histone Demethylases | 1 | 2020 | 321 | 0.150 |
Why?
|
| Gene Dosage | 4 | 2015 | 1252 | 0.150 |
Why?
|
| Platinum | 2 | 2015 | 231 | 0.150 |
Why?
|
| Carcinoma, Lobular | 1 | 2021 | 484 | 0.150 |
Why?
|
| Diagnostic Imaging | 1 | 2011 | 3503 | 0.150 |
Why?
|
| Phosphoric Diester Hydrolases | 1 | 2018 | 197 | 0.150 |
Why?
|
| Multiple Myeloma | 4 | 2007 | 5185 | 0.150 |
Why?
|
| Aryl Hydrocarbon Receptor Nuclear Translocator | 1 | 2017 | 38 | 0.150 |
Why?
|
| Travel | 1 | 2023 | 788 | 0.150 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 2 | 2022 | 552 | 0.150 |
Why?
|
| Cadherins | 1 | 2021 | 907 | 0.150 |
Why?
|
| Warfarin | 2 | 2022 | 1497 | 0.150 |
Why?
|
| Viral Envelope Proteins | 1 | 2020 | 635 | 0.140 |
Why?
|
| Robotics | 3 | 2014 | 899 | 0.140 |
Why?
|
| Lymphocyte Count | 2 | 2019 | 793 | 0.140 |
Why?
|
| Antibodies, Anti-Idiotypic | 1 | 2018 | 349 | 0.140 |
Why?
|
| Radioisotopes | 1 | 2018 | 500 | 0.140 |
Why?
|
| Thrombosis | 1 | 2010 | 2968 | 0.140 |
Why?
|
| Cost of Illness | 3 | 2015 | 1859 | 0.140 |
Why?
|
| Gene Deletion | 3 | 2020 | 2749 | 0.140 |
Why?
|
| Amino Acid Transport System y+ | 1 | 2016 | 35 | 0.140 |
Why?
|
| Sequence Analysis, DNA | 5 | 2021 | 4803 | 0.140 |
Why?
|
| Venous Thrombosis | 2 | 2003 | 1240 | 0.140 |
Why?
|
| Animals | 22 | 2024 | 168660 | 0.140 |
Why?
|
| Seminoma | 2 | 2015 | 139 | 0.140 |
Why?
|
| Cytosine Deaminase | 1 | 2016 | 68 | 0.140 |
Why?
|
| Chemokine CXCL9 | 1 | 2016 | 132 | 0.140 |
Why?
|
| T-Lymphocytes | 4 | 2024 | 10179 | 0.140 |
Why?
|
| Muscle Neoplasms | 1 | 2017 | 139 | 0.140 |
Why?
|
| Retreatment | 4 | 2021 | 609 | 0.140 |
Why?
|
| Microsatellite Repeats | 1 | 2018 | 799 | 0.140 |
Why?
|
| Synovitis | 1 | 2017 | 209 | 0.140 |
Why?
|
| Receptors, CXCR4 | 1 | 2021 | 727 | 0.130 |
Why?
|
| Neuroendocrine Tumors | 1 | 2022 | 594 | 0.130 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2020 | 2503 | 0.130 |
Why?
|
| Down-Regulation | 2 | 2018 | 3000 | 0.130 |
Why?
|
| Complementarity Determining Regions | 1 | 2016 | 149 | 0.130 |
Why?
|
| Early Termination of Clinical Trials | 1 | 2015 | 68 | 0.130 |
Why?
|
| Publication Bias | 2 | 2014 | 162 | 0.130 |
Why?
|
| Biopsy | 6 | 2019 | 6750 | 0.130 |
Why?
|
| Histocompatibility Antigens Class II | 1 | 2020 | 1475 | 0.130 |
Why?
|
| Health Status | 3 | 2022 | 4031 | 0.130 |
Why?
|
| Colorectal Neoplasms | 7 | 2021 | 6773 | 0.130 |
Why?
|
| Benzimidazoles | 1 | 2021 | 850 | 0.130 |
Why?
|
| Fanconi Anemia Complementation Group Proteins | 1 | 2015 | 100 | 0.130 |
Why?
|
| Air Pollution, Indoor | 1 | 2022 | 857 | 0.130 |
Why?
|
| Vaccines, Subunit | 1 | 2016 | 168 | 0.130 |
Why?
|
| Obesity | 3 | 2022 | 12744 | 0.130 |
Why?
|
| Anti-Infective Agents | 1 | 2023 | 971 | 0.130 |
Why?
|
| Protein Kinases | 2 | 2015 | 1640 | 0.130 |
Why?
|
| Multigene Family | 1 | 2018 | 1101 | 0.130 |
Why?
|
| Health Status Disparities | 3 | 2023 | 1796 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2021 | 988 | 0.130 |
Why?
|
| Academic Medical Centers | 3 | 2017 | 2760 | 0.130 |
Why?
|
| Epidemiologic Studies | 2 | 2021 | 676 | 0.130 |
Why?
|
| Research | 1 | 2024 | 1999 | 0.130 |
Why?
|
| Creatinine | 2 | 2020 | 1918 | 0.130 |
Why?
|
| Chi-Square Distribution | 5 | 2018 | 3503 | 0.130 |
Why?
|
| Chemokine CXCL10 | 1 | 2016 | 305 | 0.130 |
Why?
|
| Disease Management | 5 | 2020 | 2459 | 0.130 |
Why?
|
| Body Mass Index | 6 | 2022 | 12718 | 0.130 |
Why?
|
| Proteinuria | 1 | 2018 | 658 | 0.130 |
Why?
|
| Receptor Tyrosine Kinase-like Orphan Receptors | 1 | 2014 | 42 | 0.130 |
Why?
|
| Piperidines | 2 | 2014 | 1601 | 0.130 |
Why?
|
| Immunomodulation | 1 | 2018 | 541 | 0.120 |
Why?
|
| Health Care Costs | 3 | 2020 | 3207 | 0.120 |
Why?
|
| Drug Approval | 1 | 2021 | 742 | 0.120 |
Why?
|
| Comorbidity | 7 | 2021 | 10380 | 0.120 |
Why?
|
| Enzyme Inhibitors | 2 | 2010 | 3794 | 0.120 |
Why?
|
| Mucositis | 1 | 2015 | 100 | 0.120 |
Why?
|
| DNA Helicases | 1 | 2020 | 861 | 0.120 |
Why?
|
| Accidents | 1 | 2015 | 164 | 0.120 |
Why?
|
| Interferon-gamma | 3 | 2020 | 3205 | 0.120 |
Why?
|
| Bone Remodeling | 1 | 2018 | 569 | 0.120 |
Why?
|
| Antigen Presentation | 1 | 2020 | 1283 | 0.120 |
Why?
|
| Filgrastim | 1 | 2014 | 133 | 0.120 |
Why?
|
| Placebos | 3 | 2017 | 1674 | 0.120 |
Why?
|
| Suicide | 2 | 2015 | 1476 | 0.120 |
Why?
|
| Xeroderma Pigmentosum Group D Protein | 1 | 2014 | 105 | 0.120 |
Why?
|
| Doxorubicin | 2 | 2014 | 2234 | 0.120 |
Why?
|
| Heart Neoplasms | 1 | 2017 | 374 | 0.120 |
Why?
|
| Confidence Intervals | 3 | 2015 | 2971 | 0.120 |
Why?
|
| Insurance Benefits | 1 | 2016 | 183 | 0.120 |
Why?
|
| Heat-Shock Proteins | 1 | 2018 | 820 | 0.120 |
Why?
|
| Drug Therapy | 2 | 2014 | 496 | 0.120 |
Why?
|
| Drug Utilization | 1 | 2020 | 1183 | 0.120 |
Why?
|
| Video Recording | 1 | 2019 | 949 | 0.120 |
Why?
|
| Recombinant Proteins | 4 | 2018 | 6620 | 0.120 |
Why?
|
| Perioperative Care | 2 | 2019 | 1002 | 0.120 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2013 | 22 | 0.120 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2020 | 1335 | 0.120 |
Why?
|
| Oncogene Proteins, Fusion | 1 | 2022 | 1581 | 0.120 |
Why?
|
| Quality of Health Care | 3 | 2019 | 4370 | 0.120 |
Why?
|
| Urban Population | 1 | 2022 | 2021 | 0.110 |
Why?
|
| Cardiovascular Diseases | 4 | 2021 | 15142 | 0.110 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 1799 | 0.110 |
Why?
|
| Hyperbilirubinemia | 1 | 2013 | 77 | 0.110 |
Why?
|
| Preventive Health Services | 1 | 2018 | 575 | 0.110 |
Why?
|
| Germ Cells | 3 | 2022 | 629 | 0.110 |
Why?
|
| Molecular Chaperones | 1 | 2018 | 742 | 0.110 |
Why?
|
| Propensity Score | 5 | 2019 | 1781 | 0.110 |
Why?
|
| Geriatrics | 1 | 2018 | 396 | 0.110 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2013 | 78 | 0.110 |
Why?
|
| Glucuronosyltransferase | 1 | 2013 | 128 | 0.110 |
Why?
|
| Liver Function Tests | 1 | 2014 | 529 | 0.110 |
Why?
|
| Drug Therapy, Combination | 5 | 2020 | 6487 | 0.110 |
Why?
|
| Muscles | 1 | 2018 | 1613 | 0.110 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2013 | 125 | 0.110 |
Why?
|
| Apoptosis | 3 | 2019 | 9718 | 0.110 |
Why?
|
| Radiotherapy | 4 | 2017 | 1533 | 0.110 |
Why?
|
| Clinical Protocols | 1 | 2019 | 1459 | 0.110 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2018 | 783 | 0.110 |
Why?
|
| Muscle, Smooth | 1 | 2017 | 934 | 0.110 |
Why?
|
| Morpholines | 1 | 2016 | 571 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 379 | 0.110 |
Why?
|
| Epigenomics | 3 | 2023 | 903 | 0.110 |
Why?
|
| Hypocalcemia | 1 | 2014 | 191 | 0.110 |
Why?
|
| Oligopeptides | 1 | 2018 | 1188 | 0.110 |
Why?
|
| Information Dissemination | 1 | 2021 | 1099 | 0.110 |
Why?
|
| Endpoint Determination | 1 | 2015 | 601 | 0.110 |
Why?
|
| Drug Interactions | 1 | 2017 | 1460 | 0.110 |
Why?
|
| Aminopyridines | 1 | 2016 | 543 | 0.110 |
Why?
|
| Urology | 1 | 2017 | 396 | 0.110 |
Why?
|
| Heme Oxygenase-1 | 1 | 2015 | 381 | 0.110 |
Why?
|
| Oligodeoxyribonucleotides | 1 | 2013 | 708 | 0.100 |
Why?
|
| Aptamers, Nucleotide | 1 | 2013 | 166 | 0.100 |
Why?
|
| Serum Albumin | 1 | 2015 | 675 | 0.100 |
Why?
|
| Stomach Neoplasms | 1 | 2021 | 1332 | 0.100 |
Why?
|
| Citric Acid Cycle | 1 | 2013 | 231 | 0.100 |
Why?
|
| Practice Guidelines as Topic | 5 | 2021 | 7270 | 0.100 |
Why?
|
| MicroRNAs | 4 | 2016 | 3750 | 0.100 |
Why?
|
| Vaccination | 2 | 2021 | 3275 | 0.100 |
Why?
|
| Fee-for-Service Plans | 1 | 2017 | 694 | 0.100 |
Why?
|
| Lymph Nodes | 4 | 2017 | 3476 | 0.100 |
Why?
|
| Leukocyte Count | 1 | 2016 | 1588 | 0.100 |
Why?
|
| Alleles | 4 | 2021 | 6934 | 0.100 |
Why?
|
| Epidemiologic Methods | 3 | 2015 | 1364 | 0.100 |
Why?
|
| DNA, Neoplasm | 2 | 2016 | 1758 | 0.100 |
Why?
|
| Penis | 1 | 2013 | 214 | 0.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2002 | 1596 | 0.100 |
Why?
|
| Pyrazoles | 1 | 2022 | 1970 | 0.100 |
Why?
|
| Rural Population | 1 | 2022 | 2207 | 0.100 |
Why?
|
| Behavioral Risk Factor Surveillance System | 3 | 2016 | 199 | 0.100 |
Why?
|
| Telomere | 1 | 2017 | 910 | 0.100 |
Why?
|
| Carcinoma in Situ | 1 | 2017 | 805 | 0.100 |
Why?
|
| Community Health Services | 1 | 2016 | 650 | 0.100 |
Why?
|
| Genotype | 3 | 2015 | 12944 | 0.100 |
Why?
|
| Antigens, CD | 1 | 2021 | 4026 | 0.100 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2017 | 923 | 0.100 |
Why?
|
| Metabolomics | 1 | 2019 | 1487 | 0.100 |
Why?
|
| Treatment Refusal | 1 | 2014 | 421 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 2217 | 0.090 |
Why?
|
| C-Reactive Protein | 1 | 2022 | 3778 | 0.090 |
Why?
|
| Geriatric Assessment | 2 | 2018 | 1372 | 0.090 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2012 | 504 | 0.090 |
Why?
|
| Anticoagulants | 2 | 2022 | 4599 | 0.090 |
Why?
|
| Postoperative Period | 2 | 2018 | 1841 | 0.090 |
Why?
|
| Minority Groups | 1 | 2018 | 1222 | 0.090 |
Why?
|
| Hematologic Neoplasms | 1 | 2022 | 1832 | 0.090 |
Why?
|
| Mass Screening | 3 | 2021 | 5251 | 0.090 |
Why?
|
| Uterine Cervical Neoplasms | 3 | 2018 | 2018 | 0.090 |
Why?
|
| Data Interpretation, Statistical | 1 | 2020 | 2715 | 0.090 |
Why?
|
| Sex Factors | 7 | 2020 | 10394 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 610 | 0.090 |
Why?
|
| Energy Metabolism | 1 | 2021 | 2899 | 0.090 |
Why?
|
| Enteritis | 1 | 2011 | 165 | 0.090 |
Why?
|
| Drug Monitoring | 1 | 2016 | 953 | 0.090 |
Why?
|
| Immunosuppressive Agents | 2 | 2013 | 4152 | 0.090 |
Why?
|
| Cancer Vaccines | 3 | 2016 | 1023 | 0.090 |
Why?
|
| Proto-Oncogene Proteins c-ret | 1 | 2011 | 220 | 0.090 |
Why?
|
| Carbon Radioisotopes | 1 | 2010 | 577 | 0.090 |
Why?
|
| Reproducibility of Results | 5 | 2018 | 19894 | 0.090 |
Why?
|
| Arteries | 2 | 2012 | 1119 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2013 | 690 | 0.080 |
Why?
|
| Myocardial Contraction | 1 | 2014 | 1579 | 0.080 |
Why?
|
| Neutropenia | 2 | 2012 | 895 | 0.080 |
Why?
|
| Remission Induction | 1 | 2015 | 2384 | 0.080 |
Why?
|
| Infusions, Intravenous | 3 | 2013 | 2274 | 0.080 |
Why?
|
| Evidence-Based Medicine | 1 | 2021 | 3608 | 0.080 |
Why?
|
| Heart Conduction System | 1 | 2014 | 1047 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 634 | 0.080 |
Why?
|
| Oxygen | 1 | 2020 | 4189 | 0.080 |
Why?
|
| Gastrointestinal Diseases | 1 | 2017 | 1171 | 0.080 |
Why?
|
| Anemia, Macrocytic | 1 | 2008 | 55 | 0.080 |
Why?
|
| Artificial Intelligence | 1 | 2021 | 2210 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2018 | 3492 | 0.080 |
Why?
|
| Prednisone | 2 | 2023 | 1574 | 0.080 |
Why?
|
| Guideline Adherence | 2 | 2015 | 2265 | 0.080 |
Why?
|
| Methionine | 1 | 2010 | 590 | 0.080 |
Why?
|
| Cardiology | 1 | 2019 | 1668 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 6 | 2015 | 35409 | 0.080 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2023 | 4033 | 0.080 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2016 | 1837 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2014 | 805 | 0.080 |
Why?
|
| Nitriles | 2 | 2021 | 953 | 0.080 |
Why?
|
| Hospice Care | 1 | 2015 | 672 | 0.080 |
Why?
|
| Macrophages | 3 | 2021 | 5651 | 0.080 |
Why?
|
| Pancreatitis | 1 | 2014 | 1092 | 0.080 |
Why?
|
| Controlled Clinical Trials as Topic | 1 | 2008 | 186 | 0.080 |
Why?
|
| Karyotyping | 1 | 2009 | 1243 | 0.080 |
Why?
|
| Methotrexate | 1 | 2014 | 1726 | 0.070 |
Why?
|
| Acetaminophen | 1 | 2011 | 545 | 0.070 |
Why?
|
| Paxillin | 1 | 2007 | 86 | 0.070 |
Why?
|
| Patents as Topic | 1 | 2008 | 103 | 0.070 |
Why?
|
| Proteomics | 2 | 2017 | 3639 | 0.070 |
Why?
|
| Patient Admission | 1 | 2015 | 1380 | 0.070 |
Why?
|
| Demography | 3 | 2018 | 1653 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2012 | 1284 | 0.070 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5078 | 0.070 |
Why?
|
| Hospital Mortality | 2 | 2020 | 5316 | 0.070 |
Why?
|
| Laparoscopy | 3 | 2019 | 2148 | 0.070 |
Why?
|
| Erythropoiesis | 1 | 2011 | 706 | 0.070 |
Why?
|
| Surgery, Computer-Assisted | 2 | 2012 | 1017 | 0.070 |
Why?
|
| Genetic Variation | 3 | 2022 | 6535 | 0.070 |
Why?
|
| Transcription, Genetic | 1 | 2021 | 7719 | 0.070 |
Why?
|
| Child | 6 | 2021 | 77637 | 0.070 |
Why?
|
| alpha-Fetoproteins | 1 | 2007 | 223 | 0.070 |
Why?
|
| Hydroxychloroquine | 2 | 2020 | 412 | 0.070 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2006 | 49 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2021 | 8436 | 0.070 |
Why?
|
| Referral and Consultation | 2 | 2022 | 3530 | 0.070 |
Why?
|
| RNA, Messenger | 6 | 2016 | 13028 | 0.070 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2007 | 424 | 0.070 |
Why?
|
| Urethra | 1 | 2008 | 407 | 0.070 |
Why?
|
| Myocardial Infarction | 3 | 2013 | 11708 | 0.070 |
Why?
|
| X-Linked Inhibitor of Apoptosis Protein | 1 | 2006 | 63 | 0.070 |
Why?
|
| Endothelins | 1 | 2006 | 138 | 0.070 |
Why?
|
| Cross-Sectional Studies | 7 | 2023 | 25032 | 0.070 |
Why?
|
| Diffusion of Innovation | 1 | 2011 | 725 | 0.070 |
Why?
|
| Caveolin 1 | 1 | 2007 | 263 | 0.070 |
Why?
|
| Smoking | 2 | 2023 | 8984 | 0.070 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2011 | 1374 | 0.070 |
Why?
|
| Karnofsky Performance Status | 2 | 2017 | 173 | 0.070 |
Why?
|
| Dementia | 1 | 2019 | 2518 | 0.070 |
Why?
|
| Biological Products | 1 | 2014 | 859 | 0.070 |
Why?
|
| Chromatin | 2 | 2016 | 2931 | 0.060 |
Why?
|
| Daptomycin | 1 | 2005 | 73 | 0.060 |
Why?
|
| HEK293 Cells | 3 | 2020 | 4204 | 0.060 |
Why?
|
| Radiology | 1 | 2019 | 2099 | 0.060 |
Why?
|
| Chorionic Gonadotropin | 1 | 2007 | 475 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2006 | 365 | 0.060 |
Why?
|
| Keratins | 1 | 2006 | 515 | 0.060 |
Why?
|
| Interferons | 1 | 2008 | 706 | 0.060 |
Why?
|
| Antihypertensive Agents | 1 | 2014 | 2047 | 0.060 |
Why?
|
| Enterococcus faecium | 1 | 2005 | 99 | 0.060 |
Why?
|
| Decision Support Techniques | 1 | 2015 | 1956 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2013 | 2440 | 0.060 |
Why?
|
| RNA-Binding Proteins | 1 | 2013 | 1900 | 0.060 |
Why?
|
| Longitudinal Studies | 3 | 2019 | 13980 | 0.060 |
Why?
|
| Epigenesis, Genetic | 2 | 2018 | 3645 | 0.060 |
Why?
|
| Carboplatin | 2 | 2020 | 801 | 0.060 |
Why?
|
| Eligibility Determination | 2 | 2021 | 404 | 0.060 |
Why?
|
| Hyperglycemia | 1 | 2013 | 1373 | 0.060 |
Why?
|
| Activated Protein C Resistance | 1 | 2003 | 21 | 0.060 |
Why?
|
| Testosterone | 1 | 2014 | 2297 | 0.060 |
Why?
|
| Multicenter Studies as Topic | 2 | 2019 | 1676 | 0.060 |
Why?
|
| Medical Records | 1 | 2009 | 1412 | 0.060 |
Why?
|
| Communicable Disease Control | 2 | 2021 | 856 | 0.060 |
Why?
|
| Pyrrolidines | 1 | 2006 | 341 | 0.060 |
Why?
|
| Random Allocation | 2 | 2019 | 2429 | 0.060 |
Why?
|
| Weight Gain | 1 | 2014 | 2294 | 0.060 |
Why?
|
| Sphingosine | 1 | 2006 | 306 | 0.060 |
Why?
|
| DNA Primers | 1 | 2008 | 2891 | 0.060 |
Why?
|
| Polymerase Chain Reaction | 1 | 2013 | 6170 | 0.060 |
Why?
|
| Lysophospholipids | 1 | 2006 | 330 | 0.060 |
Why?
|
| Levivirus | 1 | 2023 | 13 | 0.060 |
Why?
|
| Genetic Heterogeneity | 2 | 2018 | 733 | 0.060 |
Why?
|
| Terminal Care | 1 | 2015 | 1694 | 0.060 |
Why?
|
| Radiopharmaceuticals | 1 | 2013 | 2647 | 0.060 |
Why?
|
| Castration | 1 | 2023 | 158 | 0.060 |
Why?
|
| INDEL Mutation | 2 | 2015 | 279 | 0.060 |
Why?
|
| Factor V | 1 | 2003 | 178 | 0.060 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 1178 | 0.050 |
Why?
|
| Lung Diseases | 1 | 2013 | 1887 | 0.050 |
Why?
|
| Survival | 2 | 2013 | 163 | 0.050 |
Why?
|
| Prevalence | 4 | 2021 | 15211 | 0.050 |
Why?
|
| Drug Costs | 1 | 2010 | 1105 | 0.050 |
Why?
|
| Overweight | 1 | 2014 | 2371 | 0.050 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2005 | 340 | 0.050 |
Why?
|
| Caspases | 1 | 2006 | 928 | 0.050 |
Why?
|
| Bone and Bones | 1 | 2013 | 2576 | 0.050 |
Why?
|
| Androstadienes | 1 | 2004 | 345 | 0.050 |
Why?
|
| Mendelian Randomization Analysis | 2 | 2019 | 967 | 0.050 |
Why?
|
| Pancreatic Neoplasms | 2 | 2011 | 5264 | 0.050 |
Why?
|
| Structure-Activity Relationship | 1 | 2008 | 3128 | 0.050 |
Why?
|
| Delivery of Health Care | 1 | 2020 | 5319 | 0.050 |
Why?
|
| Chromosomal Instability | 1 | 2023 | 183 | 0.050 |
Why?
|
| Arthritis, Rheumatoid | 1 | 2018 | 3712 | 0.050 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 12954 | 0.050 |
Why?
|
| Leukemia, Myeloid | 1 | 2005 | 707 | 0.050 |
Why?
|
| Tennessee | 1 | 2021 | 117 | 0.050 |
Why?
|
| Free Radicals | 1 | 2002 | 237 | 0.050 |
Why?
|
| Aging | 2 | 2018 | 8655 | 0.050 |
Why?
|
| Nitric Oxide | 1 | 2010 | 2132 | 0.050 |
Why?
|
| Oxidative Stress | 2 | 2023 | 3082 | 0.050 |
Why?
|
| Receptors, Estrogen | 2 | 2006 | 2190 | 0.050 |
Why?
|
| London | 1 | 2021 | 233 | 0.050 |
Why?
|
| Nutrition Disorders | 1 | 2022 | 211 | 0.050 |
Why?
|
| Depressive Disorder | 1 | 2014 | 3744 | 0.050 |
Why?
|
| Biopsy, Needle | 2 | 2018 | 1639 | 0.050 |
Why?
|
| Child, Preschool | 2 | 2021 | 40964 | 0.050 |
Why?
|
| Microfilament Proteins | 1 | 2006 | 1152 | 0.050 |
Why?
|
| Angiotensin I | 1 | 2021 | 57 | 0.050 |
Why?
|
| Paraproteinemias | 1 | 2003 | 246 | 0.050 |
Why?
|
| Urinary Bladder | 2 | 2017 | 1173 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2017 | 4556 | 0.050 |
Why?
|
| Censuses | 1 | 2022 | 200 | 0.050 |
Why?
|
| Heparin, Low-Molecular-Weight | 1 | 2022 | 339 | 0.050 |
Why?
|
| Liver | 2 | 2013 | 7479 | 0.050 |
Why?
|
| Length of Stay | 4 | 2017 | 6311 | 0.050 |
Why?
|
| Bone Marrow | 1 | 2011 | 2951 | 0.050 |
Why?
|
| Severity of Illness Index | 4 | 2022 | 15526 | 0.050 |
Why?
|
| International Normalized Ratio | 1 | 2002 | 367 | 0.050 |
Why?
|
| Vincristine | 1 | 2002 | 1039 | 0.050 |
Why?
|
| ras Proteins | 2 | 2016 | 1059 | 0.050 |
Why?
|
| Morbidity | 2 | 2017 | 1768 | 0.050 |
Why?
|
| Mice, Nude | 2 | 2019 | 3680 | 0.050 |
Why?
|
| Self Report | 3 | 2016 | 3550 | 0.050 |
Why?
|
| Inpatients | 1 | 2012 | 2515 | 0.050 |
Why?
|
| Patient Satisfaction | 1 | 2013 | 3391 | 0.050 |
Why?
|
| Japan | 2 | 2015 | 1360 | 0.050 |
Why?
|
| Androstenes | 1 | 2021 | 168 | 0.050 |
Why?
|
| Pelvis | 2 | 2017 | 730 | 0.050 |
Why?
|
| Probability | 2 | 2020 | 2505 | 0.040 |
Why?
|
| Phenylthiohydantoin | 1 | 2021 | 193 | 0.040 |
Why?
|
| Hepatocyte Nuclear Factor 3-alpha | 1 | 2020 | 170 | 0.040 |
Why?
|
| Anxiety | 1 | 2014 | 4288 | 0.040 |
Why?
|
| Age of Onset | 3 | 2015 | 3268 | 0.040 |
Why?
|
| Aneuploidy | 1 | 2023 | 530 | 0.040 |
Why?
|
| Coronary Disease | 1 | 2014 | 6078 | 0.040 |
Why?
|
| Thrombophilia | 1 | 2002 | 305 | 0.040 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 1 | 2002 | 693 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2020 | 234 | 0.040 |
Why?
|
| History, 21st Century | 2 | 2015 | 1532 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2020 | 435 | 0.040 |
Why?
|
| Carcinoma, Ductal, Breast | 1 | 2007 | 1100 | 0.040 |
Why?
|
| Benzamides | 2 | 2021 | 1383 | 0.040 |
Why?
|
| Case-Control Studies | 5 | 2017 | 21733 | 0.040 |
Why?
|
| Molecular Sequence Annotation | 1 | 2021 | 528 | 0.040 |
Why?
|
| Massachusetts | 3 | 2021 | 8660 | 0.040 |
Why?
|
| Granzymes | 1 | 2020 | 271 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2003 | 690 | 0.040 |
Why?
|
| Kynurenine | 1 | 2019 | 139 | 0.040 |
Why?
|
| Peptidyl-Dipeptidase A | 1 | 2021 | 365 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 196 | 0.040 |
Why?
|
| Hospitalization | 2 | 2015 | 10259 | 0.040 |
Why?
|
| Gene Fusion | 1 | 2022 | 371 | 0.040 |
Why?
|
| Patient Advocacy | 1 | 2021 | 353 | 0.040 |
Why?
|
| Membrane Proteins | 1 | 2015 | 7880 | 0.040 |
Why?
|
| Triazoles | 1 | 2004 | 904 | 0.040 |
Why?
|
| Th1-Th2 Balance | 1 | 2018 | 38 | 0.040 |
Why?
|
| Furans | 1 | 2019 | 193 | 0.040 |
Why?
|
| Kidney Function Tests | 1 | 2020 | 684 | 0.040 |
Why?
|
| Paresthesia | 1 | 2019 | 160 | 0.040 |
Why?
|
| Cluster Analysis | 2 | 2015 | 2712 | 0.040 |
Why?
|
| Adenosine Monophosphate | 1 | 2020 | 275 | 0.040 |
Why?
|
| Promoter Regions, Genetic | 2 | 2024 | 5867 | 0.040 |
Why?
|
| Lipid Peroxidation | 1 | 2019 | 270 | 0.040 |
Why?
|
| Kidney Failure, Chronic | 1 | 2011 | 2534 | 0.040 |
Why?
|
| Alanine | 1 | 2020 | 571 | 0.040 |
Why?
|
| Adjuvants, Immunologic | 1 | 2023 | 999 | 0.040 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2005 | 1030 | 0.040 |
Why?
|
| Public Health | 2 | 2021 | 2603 | 0.040 |
Why?
|
| Angiotensin II | 1 | 2021 | 880 | 0.040 |
Why?
|
| Mammography | 2 | 2021 | 2475 | 0.040 |
Why?
|
| History, 20th Century | 2 | 2015 | 2736 | 0.040 |
Why?
|
| Tryptophan | 1 | 2019 | 478 | 0.040 |
Why?
|
| Administration, Intravesical | 1 | 2017 | 91 | 0.040 |
Why?
|
| Thyroid Function Tests | 1 | 2018 | 286 | 0.040 |
Why?
|
| Models, Economic | 2 | 2012 | 712 | 0.040 |
Why?
|
| Anemia | 1 | 2006 | 1502 | 0.040 |
Why?
|
| Troponin T | 1 | 2022 | 754 | 0.040 |
Why?
|
| Oncogenes | 1 | 2023 | 1265 | 0.040 |
Why?
|
| Patient Care Team | 2 | 2022 | 2528 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2002 | 2241 | 0.040 |
Why?
|
| Plasma | 1 | 2020 | 575 | 0.040 |
Why?
|
| HIV Infections | 1 | 2023 | 16715 | 0.040 |
Why?
|
| Sex Distribution | 2 | 2014 | 2298 | 0.040 |
Why?
|
| Health Facilities | 1 | 2022 | 572 | 0.040 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 2020 | 794 | 0.040 |
Why?
|
| Organ Size | 2 | 2013 | 2241 | 0.030 |
Why?
|
| Depression | 1 | 2016 | 7760 | 0.030 |
Why?
|
| Cricetulus | 1 | 2018 | 818 | 0.030 |
Why?
|
| Marriage | 1 | 2018 | 339 | 0.030 |
Why?
|
| Korea | 1 | 2015 | 99 | 0.030 |
Why?
|
| Cryotherapy | 1 | 2017 | 155 | 0.030 |
Why?
|
| Social Class | 2 | 2016 | 1997 | 0.030 |
Why?
|
| Philippines | 1 | 2015 | 86 | 0.030 |
Why?
|
| Educational Status | 2 | 2014 | 2540 | 0.030 |
Why?
|
| Gene Knockout Techniques | 1 | 2019 | 807 | 0.030 |
Why?
|
| Computational Biology | 2 | 2019 | 3515 | 0.030 |
Why?
|
| Alternative Splicing | 1 | 2021 | 1117 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2017 | 288 | 0.030 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 612 | 0.030 |
Why?
|
| DNA Repair | 2 | 2015 | 2045 | 0.030 |
Why?
|
| Antibodies | 1 | 2024 | 2459 | 0.030 |
Why?
|
| Mortality | 2 | 2019 | 2862 | 0.030 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2006 | 2914 | 0.030 |
Why?
|
| Bayes Theorem | 1 | 2023 | 2307 | 0.030 |
Why?
|
| Forkhead Transcription Factors | 1 | 2023 | 1613 | 0.030 |
Why?
|
| Genes, Neurofibromatosis 2 | 1 | 2015 | 124 | 0.030 |
Why?
|
| Fumarate Hydratase | 1 | 2015 | 47 | 0.030 |
Why?
|
| Cost Sharing | 1 | 2019 | 407 | 0.030 |
Why?
|
| CHO Cells | 1 | 2018 | 1409 | 0.030 |
Why?
|
| Rad51 Recombinase | 1 | 2015 | 189 | 0.030 |
Why?
|
| Cystoscopy | 1 | 2015 | 133 | 0.030 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2022 | 1516 | 0.030 |
Why?
|
| Epidemics | 1 | 2021 | 523 | 0.030 |
Why?
|
| Vietnam | 1 | 2015 | 408 | 0.030 |
Why?
|
| Genes, p16 | 1 | 2015 | 157 | 0.030 |
Why?
|
| Heparin | 1 | 2002 | 1637 | 0.030 |
Why?
|
| Chromosome Breakpoints | 1 | 2014 | 98 | 0.030 |
Why?
|
| Syndrome | 1 | 2021 | 3249 | 0.030 |
Why?
|
| Kidney Tubules, Collecting | 1 | 2015 | 178 | 0.030 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2011 | 8939 | 0.030 |
Why?
|
| Acute Disease | 2 | 2021 | 7150 | 0.030 |
Why?
|
| Positron-Emission Tomography | 1 | 2010 | 6237 | 0.030 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2023 | 1624 | 0.030 |
Why?
|
| Vena Cava, Inferior | 1 | 2017 | 439 | 0.030 |
Why?
|
| Androgen Receptor Antagonists | 1 | 2015 | 114 | 0.030 |
Why?
|
| Blood Cell Count | 1 | 2015 | 403 | 0.030 |
Why?
|
| Cardiovascular System | 1 | 2022 | 828 | 0.030 |
Why?
|
| BCG Vaccine | 1 | 2017 | 369 | 0.030 |
Why?
|
| Delayed Diagnosis | 1 | 2018 | 441 | 0.030 |
Why?
|
| Retroperitoneal Space | 1 | 2014 | 176 | 0.030 |
Why?
|
| Goserelin | 1 | 2014 | 129 | 0.030 |
Why?
|
| Cytidine Deaminase | 1 | 2016 | 252 | 0.030 |
Why?
|
| Gilbert Disease | 1 | 2013 | 4 | 0.030 |
Why?
|
| Receptors, Immunologic | 1 | 2020 | 1423 | 0.030 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2020 | 1683 | 0.030 |
Why?
|
| Patient Protection and Affordable Care Act | 2 | 2014 | 1209 | 0.030 |
Why?
|
| Cell Line | 2 | 2020 | 15993 | 0.030 |
Why?
|
| Drug Substitution | 1 | 2016 | 281 | 0.030 |
Why?
|
| Models, Molecular | 2 | 2014 | 5445 | 0.030 |
Why?
|
| Statistics as Topic | 1 | 2020 | 2369 | 0.030 |
Why?
|
| Pedigree | 1 | 2021 | 4643 | 0.030 |
Why?
|
| Natural Language Processing | 1 | 2021 | 1041 | 0.030 |
Why?
|
| Cost Savings | 1 | 2019 | 925 | 0.030 |
Why?
|
| Community Health Centers | 1 | 2017 | 428 | 0.030 |
Why?
|
| Myeloid-Lymphoid Leukemia Protein | 1 | 2016 | 294 | 0.030 |
Why?
|
| Brazil | 1 | 2017 | 1264 | 0.030 |
Why?
|
| United States Food and Drug Administration | 1 | 2021 | 1582 | 0.030 |
Why?
|
| Asia | 1 | 2015 | 609 | 0.030 |
Why?
|
| Microtubule-Associated Proteins | 1 | 2018 | 1083 | 0.030 |
Why?
|
| Analysis of Variance | 2 | 2014 | 6356 | 0.030 |
Why?
|
| Cardiotoxins | 1 | 2013 | 41 | 0.030 |
Why?
|
| Diaphragm | 1 | 2014 | 349 | 0.030 |
Why?
|
| Injections, Intravenous | 1 | 2015 | 1422 | 0.030 |
Why?
|
| Colonoscopy | 1 | 2021 | 1367 | 0.030 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2023 | 3758 | 0.030 |
Why?
|
| Comparative Genomic Hybridization | 1 | 2014 | 496 | 0.030 |
Why?
|
| Leuprolide | 1 | 2014 | 321 | 0.030 |
Why?
|
| Biomarkers, Pharmacological | 1 | 2013 | 162 | 0.030 |
Why?
|
| Adaptation, Physiological | 1 | 2019 | 1311 | 0.030 |
Why?
|
| Gene Amplification | 1 | 2017 | 1063 | 0.030 |
Why?
|
| Diagnostic Tests, Routine | 1 | 2018 | 782 | 0.030 |
Why?
|
| Genome | 1 | 2021 | 1806 | 0.030 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2016 | 780 | 0.030 |
Why?
|
| Patient Readmission | 2 | 2017 | 3117 | 0.030 |
Why?
|
| Delphi Technique | 1 | 2015 | 777 | 0.030 |
Why?
|
| Chromosomal Proteins, Non-Histone | 1 | 2018 | 735 | 0.030 |
Why?
|
| Singapore | 1 | 2013 | 295 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 2016 | 805 | 0.030 |
Why?
|
| Life Expectancy | 1 | 2019 | 1184 | 0.030 |
Why?
|
| Chromosomes, Human | 1 | 2014 | 457 | 0.030 |
Why?
|
| Genetic Markers | 1 | 2019 | 2634 | 0.030 |
Why?
|
| Immunity | 1 | 2018 | 1013 | 0.030 |
Why?
|
| Health Care Surveys | 1 | 2019 | 2453 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2015 | 350 | 0.030 |
Why?
|
| Disease Susceptibility | 1 | 2019 | 1781 | 0.030 |
Why?
|
| Medication Therapy Management | 1 | 2013 | 127 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2021 | 2540 | 0.030 |
Why?
|
| Gene Rearrangement | 1 | 2017 | 1179 | 0.030 |
Why?
|
| Bilirubin | 1 | 2013 | 425 | 0.030 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2014 | 657 | 0.020 |
Why?
|
| Homozygote | 1 | 2016 | 1787 | 0.020 |
Why?
|
| Advisory Committees | 1 | 2015 | 775 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2023 | 2961 | 0.020 |
Why?
|
| CpG Islands | 1 | 2015 | 1170 | 0.020 |
Why?
|
| Republic of Korea | 1 | 2013 | 538 | 0.020 |
Why?
|
| Quantitative Trait Loci | 1 | 2019 | 2018 | 0.020 |
Why?
|
| 6-Ketoprostaglandin F1 alpha | 1 | 2010 | 83 | 0.020 |
Why?
|
| Blood Pressure | 2 | 2019 | 8551 | 0.020 |
Why?
|
| Office Visits | 1 | 2015 | 598 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2019 | 3547 | 0.020 |
Why?
|
| Patient-Centered Care | 1 | 2021 | 1438 | 0.020 |
Why?
|
| Coculture Techniques | 1 | 2015 | 1342 | 0.020 |
Why?
|
| Denmark | 1 | 2013 | 738 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2020 | 2107 | 0.020 |
Why?
|
| Conserved Sequence | 1 | 2014 | 1202 | 0.020 |
Why?
|
| BRCA2 Protein | 1 | 2015 | 794 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2022 | 2568 | 0.020 |
Why?
|
| Iron | 1 | 2019 | 1774 | 0.020 |
Why?
|
| Internationality | 1 | 2016 | 1002 | 0.020 |
Why?
|
| HLA Antigens | 1 | 2016 | 1382 | 0.020 |
Why?
|
| RNA-Induced Silencing Complex | 1 | 2010 | 55 | 0.020 |
Why?
|
| T-Lymphocytes, Regulatory | 1 | 2024 | 2988 | 0.020 |
Why?
|
| RNA Interference | 1 | 2019 | 2890 | 0.020 |
Why?
|
| Transforming Growth Factor beta | 1 | 2018 | 2006 | 0.020 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2015 | 738 | 0.020 |
Why?
|
| Risk Adjustment | 1 | 2014 | 594 | 0.020 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2015 | 1213 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2016 | 2879 | 0.020 |
Why?
|
| China | 1 | 2015 | 2243 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2014 | 2034 | 0.020 |
Why?
|
| Health Occupations | 1 | 2011 | 224 | 0.020 |
Why?
|
| Antineoplastic Protocols | 1 | 2009 | 50 | 0.020 |
Why?
|
| Cyclic GMP | 1 | 2010 | 408 | 0.020 |
Why?
|
| Ventricular Function, Left | 1 | 2022 | 3660 | 0.020 |
Why?
|
| DNA, Mitochondrial | 1 | 2014 | 815 | 0.020 |
Why?
|
| Leukocytes | 1 | 2017 | 2044 | 0.020 |
Why?
|
| BRCA1 Protein | 1 | 2015 | 1148 | 0.020 |
Why?
|
| Protein Transport | 1 | 2015 | 1988 | 0.020 |
Why?
|
| Cost-Benefit Analysis | 2 | 2012 | 5388 | 0.020 |
Why?
|
| Research Design | 2 | 2014 | 5983 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2022 | 3679 | 0.020 |
Why?
|
| Health Surveys | 1 | 2018 | 4036 | 0.020 |
Why?
|
| Military Personnel | 1 | 2017 | 1133 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2019 | 1643 | 0.020 |
Why?
|
| Norway | 1 | 2009 | 448 | 0.020 |
Why?
|
| Peptide Fragments | 1 | 2021 | 5096 | 0.020 |
Why?
|
| Europe | 1 | 2015 | 3336 | 0.020 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2018 | 2944 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2009 | 513 | 0.020 |
Why?
|
| Erythrocyte Indices | 1 | 2008 | 146 | 0.020 |
Why?
|
| Transurethral Resection of Prostate | 1 | 2008 | 83 | 0.020 |
Why?
|
| Alberta | 1 | 2007 | 64 | 0.020 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2015 | 1691 | 0.020 |
Why?
|
| Dinoprostone | 1 | 2010 | 601 | 0.020 |
Why?
|
| Antiviral Agents | 1 | 2020 | 2984 | 0.020 |
Why?
|
| Quebec | 1 | 2007 | 134 | 0.020 |
Why?
|
| Chromosome Aberrations | 1 | 2014 | 1811 | 0.020 |
Why?
|
| Genetic Loci | 1 | 2017 | 2575 | 0.020 |
Why?
|
| Patient Compliance | 1 | 2018 | 2683 | 0.020 |
Why?
|
| Genetic Testing | 1 | 2020 | 3439 | 0.020 |
Why?
|
| Lipids | 1 | 2019 | 3307 | 0.020 |
Why?
|
| Health Personnel | 1 | 2021 | 3217 | 0.020 |
Why?
|
| Hematologic Tests | 1 | 2008 | 240 | 0.020 |
Why?
|
| Fatal Outcome | 1 | 2012 | 1851 | 0.020 |
Why?
|
| Poland | 1 | 2007 | 184 | 0.020 |
Why?
|
| Cardiopulmonary Resuscitation | 1 | 2015 | 980 | 0.020 |
Why?
|
| Parenteral Nutrition | 1 | 2012 | 650 | 0.020 |
Why?
|
| Decision Making | 1 | 2021 | 3887 | 0.020 |
Why?
|
| Databases as Topic | 1 | 2009 | 474 | 0.020 |
Why?
|
| Stroke | 1 | 2010 | 9975 | 0.020 |
Why?
|
| Costs and Cost Analysis | 1 | 2013 | 1680 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2012 | 1180 | 0.020 |
Why?
|
| Ohio | 1 | 2007 | 337 | 0.020 |
Why?
|
| Wound Healing | 1 | 2018 | 2776 | 0.020 |
Why?
|
| Hormones | 1 | 2011 | 889 | 0.020 |
Why?
|
| Tumor Cells, Cultured | 1 | 2015 | 6311 | 0.020 |
Why?
|
| Internet | 1 | 2019 | 3058 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2015 | 3772 | 0.020 |
Why?
|
| Cyclic AMP | 1 | 2010 | 1472 | 0.020 |
Why?
|
| Genes, erbB-2 | 1 | 2007 | 162 | 0.020 |
Why?
|
| Albuminuria | 1 | 2010 | 681 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2021 | 9139 | 0.020 |
Why?
|
| Protein Conformation | 1 | 2014 | 4009 | 0.020 |
Why?
|
| Sweden | 1 | 2009 | 1341 | 0.020 |
Why?
|
| Receptor, Endothelin A | 1 | 2006 | 58 | 0.020 |
Why?
|
| Receptors, Endothelin | 1 | 2006 | 58 | 0.020 |
Why?
|
| France | 1 | 2007 | 517 | 0.020 |
Why?
|
| Perception | 1 | 2013 | 1198 | 0.020 |
Why?
|
| Evaluation Studies as Topic | 1 | 2008 | 1677 | 0.020 |
Why?
|
| Health Services Needs and Demand | 1 | 2014 | 1411 | 0.020 |
Why?
|
| DNA | 1 | 2020 | 7295 | 0.020 |
Why?
|
| Adenoma, Oxyphilic | 1 | 2007 | 143 | 0.020 |
Why?
|
| Cytokines | 1 | 2021 | 7324 | 0.020 |
Why?
|
| Adenocarcinoma, Clear Cell | 1 | 2007 | 221 | 0.020 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 6380 | 0.020 |
Why?
|
| Dyslipidemias | 1 | 2013 | 851 | 0.020 |
Why?
|
| Tissue Array Analysis | 1 | 2007 | 553 | 0.020 |
Why?
|
| Exercise | 1 | 2002 | 5611 | 0.020 |
Why?
|
| Quality Indicators, Health Care | 1 | 2016 | 1831 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2015 | 3749 | 0.020 |
Why?
|
| Cell Differentiation | 1 | 2022 | 11478 | 0.020 |
Why?
|
| Interpersonal Relations | 1 | 2013 | 1424 | 0.020 |
Why?
|
| Cognition | 1 | 2022 | 6759 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2014 | 2566 | 0.020 |
Why?
|
| Cell Survival | 1 | 2015 | 5881 | 0.020 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2011 | 806 | 0.020 |
Why?
|
| Endothelin-1 | 1 | 2006 | 314 | 0.020 |
Why?
|
| RNA | 1 | 2014 | 2748 | 0.020 |
Why?
|
| Blood Glucose | 1 | 2019 | 6259 | 0.010 |
Why?
|
| Insulin | 1 | 2019 | 6584 | 0.010 |
Why?
|
| Social Support | 1 | 2013 | 2118 | 0.010 |
Why?
|
| Cartilage | 1 | 2007 | 818 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2014 | 2614 | 0.010 |
Why?
|
| Age Distribution | 1 | 2009 | 2899 | 0.010 |
Why?
|
| Body Weight | 1 | 2014 | 4670 | 0.010 |
Why?
|
| Computer Simulation | 1 | 2016 | 6188 | 0.010 |
Why?
|
| Mice | 2 | 2024 | 81154 | 0.010 |
Why?
|
| Base Sequence | 1 | 2014 | 12798 | 0.010 |
Why?
|
| In Situ Hybridization | 1 | 2007 | 1952 | 0.010 |
Why?
|
| Androgens | 1 | 2010 | 1247 | 0.010 |
Why?
|
| Critical Care | 1 | 2015 | 2647 | 0.010 |
Why?
|
| Cell Movement | 1 | 2014 | 5216 | 0.010 |
Why?
|
| Poverty | 1 | 2014 | 2660 | 0.010 |
Why?
|
| Models, Theoretical | 1 | 2014 | 3587 | 0.010 |
Why?
|
| Myoglobin | 1 | 2002 | 160 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2006 | 1098 | 0.010 |
Why?
|
| Veterans | 1 | 2015 | 2519 | 0.010 |
Why?
|
| Renal Dialysis | 1 | 2011 | 1783 | 0.010 |
Why?
|
| Molecular Sequence Data | 1 | 2014 | 18107 | 0.010 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 1 | 2011 | 1377 | 0.010 |
Why?
|
| Reoperation | 1 | 2010 | 4200 | 0.010 |
Why?
|
| Mitochondria, Muscle | 1 | 2002 | 171 | 0.010 |
Why?
|
| Emotions | 1 | 2013 | 2656 | 0.010 |
Why?
|
| Rhabdomyolysis | 1 | 2002 | 150 | 0.010 |
Why?
|
| Tretinoin | 1 | 2003 | 517 | 0.010 |
Why?
|
| Mental Health | 1 | 2014 | 3012 | 0.010 |
Why?
|
| Algorithms | 1 | 2020 | 13869 | 0.010 |
Why?
|
| Physical Exertion | 1 | 2002 | 695 | 0.010 |
Why?
|
| Pain, Postoperative | 1 | 2008 | 1642 | 0.010 |
Why?
|
| Linear Models | 1 | 2008 | 5952 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2016 | 12066 | 0.010 |
Why?
|
| Muscle Contraction | 1 | 2002 | 1233 | 0.010 |
Why?
|
| Heterozygote | 1 | 2003 | 2803 | 0.010 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2019 | 11729 | 0.010 |
Why?
|
| Lung | 1 | 2013 | 9858 | 0.010 |
Why?
|
| Piperazines | 1 | 2003 | 2487 | 0.010 |
Why?
|
| Muscle, Skeletal | 1 | 2002 | 4925 | 0.000 |
Why?
|